Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) Non Operating Income (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Non Operating Income for 6 consecutive years, with -$10.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Non Operating Income fell 1046100.0% to -$10.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$36000.0, a 100.14% decrease, with the full-year FY2024 number at -$77000.0, down 100.64% from a year prior.
  • Non Operating Income was -$10.5 million for Q3 2025 at 4D Molecular Therapeutics, down from $10.4 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $12.2 million in Q4 2023 to a low of -$10.5 million in Q3 2025.
  • A 5-year average of $1.5 million and a median of $60500.0 in 2022 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: soared 406566.67% in 2023, then tumbled 1046100.0% in 2025.
  • 4D Molecular Therapeutics' Non Operating Income stood at -$456000.0 in 2021, then skyrocketed by 100.66% to $3000.0 in 2022, then skyrocketed by 406566.67% to $12.2 million in 2023, then plummeted by 100.17% to -$21000.0 in 2024, then plummeted by 49719.05% to -$10.5 million in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Non Operating Income are -$10.5 million (Q3 2025), $10.4 million (Q2 2025), and $67000.0 (Q1 2025).